VRP Verona Pharma Plc

                               Verona Pharma plc

                      ("Verona Pharma" or the "Company")

                              Director's Dealing

5 December 2014, Cardiff, UK - Verona Pharma plc (AIM: VRP.L) (the "Company")
received notification on 4 December 2014 that on that date, Mr Stuart
Bottomley, a non-executive director of the Company, acquired via his SIPP an
interest in 250,000 ordinary shares of 0.1p each in the Company ("Ordinary
Shares") at a price of 1.21 pence per share.

Following the acquisition, Mr. Bottomley will have an interest in the Company
of 19,000,000 Ordinary Shares, representing 1.88% of the Company's issued
ordinary share capital.

                                    -Ends-

For further information please contact:

Verona Pharma plc                       Tel: +44 (0)20 7863 3300
Jan-Anders Karlsson, CEO

N+1 Singer                              Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer

FTI Consulting                          Tel: +44 (0)20 3727 1000
Julia Phillips / Simon Conway

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company
focused on the development of innovative prescription medicines to treat
respiratory diseases with significant unmet medical needs, such as COPD, asthma
and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class
drug currently in Phase II trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a dual
phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and
anti-inflammatory effects, which are essential to the improvement of patients
with COPD and asthma. Verona Pharma is also building a broader franchise around
RPL554 to maximise its value, both to patients and to investors. This includes
the very significant markets for COPD and asthma maintenance therapy. The
Company is also exploring the potential of the drug in different diseases, such
as cystic fibrosis, where it is in pre-clinical testing.